Showing Results for
- Academic Journals (450)
Search Results
- 450
Academic Journals
- 450
-
From:Nature (Vol. 523, Issue 7561) Peer-ReviewedA French 18-year-old who was infected with HIV at birth remains in good health despite taking her last dose of antiretroviral drugs 12 years ago. Her exceptional case is the longest-lasting example of a person infected...
-
From:Applied Clinical Trials (Vol. 18, Issue 3) Peer-ReviewedThere has been widespread satisfaction at the decision in February to continue the DAD study (Data Collection on Adverse Events of Anti-HIV Drugs). This prospective study of HIV-infected persons under active...
-
From:Future Virology (Vol. 6, Issue 5)Author(s): Cecilia Pizzocolo [[dagger]â ] 2 , Antonella Castagna 1 , Adriano Lazzarin 1 Keywords *⪠atazanavir; darunavir; drug development; HIV protease inhibitor; HIV protease inhibitors pipeline; lopinavir;...
-
From:Indian Journal of Medical Microbiology (Vol. 26, Issue 2)Byline: V. Wiwanitkit Dear editor, Human immunodeficiency virus (HIV) infection is an important infection affecting a million of world population. The best present way in coping with the patients with HIV is...
-
From:Applied Clinical Trials (Vol. 14, Issue 1) Peer-ReviewedA BBC documentary alleged that a pediatric AIDS clinical trial forced participation in New York City foster homes by removing kids if the foster parents did not give them the drugs. It also alleged that the...
-
From:Applied Clinical Trials (Vol. 14, Issue 4) Peer-ReviewedRoche (Nutley, NJ) and Trimeris' (Durham, NC) Phase IIa trial of Fuzeon (enfuviritide) and a boosted protease inhibitor for HIV patients performed better than the inhibitor alone....
-
From:Bulletin of the World Health Organization (Vol. 79, Issue 12) Peer-ReviewedThe HIV/AIDS pandemic, which is the main theme of this month's issue, has highlighted the need for ensuring the widest possible access of medicines -- whether antiretroviral drugs in the South or anti-anthrax...
-
From:Chest (Vol. 122, Issue 3) Peer-ReviewedStudy objectives: Little information exists on the impact of antiretroviral therapies (ARTs) on HIV-related bronchoscopic activity. This study was performed to identify any changes to our pattern of use of bronchoscopy...
-
From:Family Practice News (Vol. 32, Issue 20)BARCELONA, SPAIN--Experts agree that CD4 cell count is generally the best way to judge when an asymptomatic patient infected with HIV needs to start antiviral treatment. What they find more difficult to agree on is how...
-
From:British Medical Journal (Vol. 326, Issue 7403) Peer-ReviewedIncreased access to antiretroviral drugs is vital to maintain developing countries with high rates of HIV infection. But unless treatment is properly controlled, these drugs could rapidly become useless **********...
-
From:PLoS ONE (Vol. 8, Issue 8) Peer-ReviewedAuthor(s): Justen Manasa 1,*, Richard J. Lessells 1,2, Andrew Skingsley 1, Kevindra K. Naidu 1, Marie-Louise Newell 1,3, Nuala McGrath 1,4, Tulio de Oliveira 1,5, the Southern African Treatment and Resistance Network...
-
From:Clinical Advisor (Vol. 22, Issue 11)Resistance to antiviral agents has increased among infants with HIV who live in a high prevalence setting where maternal antiretroviral therapy coverage has increased....
-
From:PharmacoEconomics and Outcomes News (Vol. 594)A patent pool for HIV/AIDS medications is expected to start up in mid 2010, according to PharmaTimes. Its establishment was decided upon by the Executive Board of UNITAID, an agency that forms part of WHO and will...
-
From:Family Practice News (Vol. 36, Issue 18)TORONTO -- The new goal of therapy for HIV-infected adults who have repeatedly failed several drug regimens should be to decrease their viral load to undetectable levels with new drug regimens, according to updated...
-
From:Family Practice News (Vol. 36, Issue 2)SAN FRANCISCO -- Efforts to develop entry inhibitors, which constitute the first new class of anti-HIV drugs in years, have hit snags that could delay the entry of these novel agents into the pharmaceutical marketplace....
-
From:British Medical Journal (Vol. 322, Issue 7288) Peer-ReviewedBristol-Myers Squibb has raised the stakes in an effort to cut the prices of drugs to treat AIDS in Africa by announcing that it will sell two antiretroviral drugs in combination for $1 (66p) a day, just below the cost...
-
From:Medicine of the Americas (Vol. 2, Issue 1) Peer-ReviewedRecommendations for initial antiretroviral treatment for persons with HIV infection have changed rapidly with the availability of potent regimens, new information from clinical trials of effectiveness and durability and...
-
From:Applied Clinical Trials (Vol. 16, Issue 1) Peer-ReviewedData from a Phase I repeat dose study of Ambrilia Biopharma's (Montreal, QC) investigational protease inhibitor for HIV/AIDS, PPL-100, support continued development of the compound. Merck (Whitehouse Station, NJ)...
-
From:Nature (Vol. 449, Issue 7160) Peer-ReviewedJ. Clin. Invest. doi:10.1172/JCI31344 (2007) A type of therapy being tested against HIV may carry a risk of boosting coronary artery disease, if results from a mouse study hold true in humans. Previously,...
-
From:Nature Medicine (Vol. 18, Issue 3) Peer-ReviewedCombination-based antiretroviral therapy has been very successful in preventing disease progression in HIV-infected individuals. However, a rational method for predicting the effect of a particular drug combination on...